As assays to selectively measure the proportion of HDL particles containing apoE become more readily available, it will be important to determine whether the levels of circulating apoE-containing HDL help to predict the risk of CAA, total brain Aβ accumulation, and cognitive decline in AD patients. The gene discussed is APOE; the disease is Alzheimer disease.